【Kissei Pharmaceutical】Share Buyback and Compensation System Introduction ｜ June 2026

Overview of the Disposition

Kissei Pharmaceutical plans to grant a total of 19,794 shares of restricted share conveyance to directors and executive officers, with payment scheduled for July 23, 2026. The disposal price is 3,940 yen per share, totaling 77,988,360 yen. This system aims to promote sustained enhancement of corporate value and shared value with shareholders. The targeted individuals will be subject to transfer restrictions for a certain period. Details of the system include restrictions on transfer periods, conditions for解除, and provisions for gratuitous acquisition.

Purpose of the System and Future Outlook

This system aims to provide stock-based rewards to targeted individuals, fostering long-term commitment from officers and management. It was approved at the Shareholders' Meeting in June 2025, aiming to improve corporate value while minimizing shareholder dilution. The payment amount will be determined based on market stock prices, and the system is expected to enhance incentives for officers, supporting the company's sustainable growth.